Press coverage about Hill-Rom (NYSE:HRC) has trended positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hill-Rom earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave press coverage about the medical technology company an impact score of 47.03828471374 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Hospital Beds Global Market Prognosticated To Perceive A Thriving Growth MRFR Unleashes Industry Insights Up To 2023 (menafn.com)
- Hill-Rom taps Imprivata to secure Welch Allyn Connex monitor data (massdevice.com)
- Zacks: Analysts Expect Hill-Rom Holdings, Inc. (HRC) Will Post Quarterly Sales of $709.03 Million (americanbankingnews.com)
- Hill-Rom Holdings, Inc. (HRC) Plans Dividend Increase – $0.20 Per Share (americanbankingnews.com)
- Hill-Rom Holdings, Inc. (HRC) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
A number of brokerages have recently issued reports on HRC. ValuEngine upgraded Hill-Rom from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Barclays restated a “buy” rating and set a $100.00 price objective on shares of Hill-Rom in a report on Wednesday, January 10th. Needham & Company LLC restated a “buy” rating on shares of Hill-Rom in a report on Friday, January 26th. Finally, Bank of America reiterated a “hold” rating on shares of Hill-Rom in a research note on Wednesday, November 22nd. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Hill-Rom has an average rating of “Buy” and a consensus target price of $95.38.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.13. The business had revenue of $669.70 million during the quarter, compared to analysts’ expectations of $670.00 million. Hill-Rom had a return on equity of 20.24% and a net margin of 7.14%. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 earnings per share. research analysts predict that Hill-Rom will post 4.62 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 23rd will be paid a $0.20 dividend. This is a boost from Hill-Rom’s previous quarterly dividend of $0.18. This represents a $0.80 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Thursday, March 22nd. Hill-Rom’s payout ratio is 24.49%.
In other Hill-Rom news, CEO John J. Greisch sold 100,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the completion of the sale, the chief executive officer now directly owns 230,851 shares in the company, valued at $19,119,079.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John J. Greisch sold 125,241 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $82.59, for a total value of $10,343,654.19. Following the sale, the chief executive officer now owns 280,851 shares of the company’s stock, valued at $23,195,484.09. The disclosure for this sale can be found here. Over the last quarter, insiders sold 226,241 shares of company stock valued at $18,708,644. 1.90% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This story was reported by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://baseballnewssource.com/2018/03/12/hill-rom-hrc-earning-positive-news-coverage-report-shows/2014671.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.